692 related articles for article (PubMed ID: 27390130)
1. Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1).
Deodhar AA; Dougados M; Baeten DL; Cheng-Chung Wei J; Geusens P; Readie A; Richards HB; Martin R; Porter B
Arthritis Rheumatol; 2016 Dec; 68(12):2901-2910. PubMed ID: 27390130
[TBL] [Abstract][Full Text] [Related]
2. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
van der Heijde DM; Revicki DA; Gooch KL; Wong RL; Kupper H; Harnam N; Thompson C; Sieper J;
Arthritis Res Ther; 2009; 11(4):R124. PubMed ID: 19686597
[TBL] [Abstract][Full Text] [Related]
3. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
Navarro-Compán V; Wei JC; Van den Bosch F; Magrey M; Wang L; Fleishaker D; Cappelleri JC; Wang C; Wu J; Dina O; Fallon L; Strand V
RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
[TBL] [Abstract][Full Text] [Related]
4. The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial.
Reveille JD; Hwang MC; Danve A; Kafka S; Peterson S; Lo KH; Kim L; Hsia EC; Chan EKH; Deodhar A
Clin Rheumatol; 2021 Apr; 40(4):1331-1341. PubMed ID: 32926247
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.
Davis JC; Revicki D; van der Heijde DM; Rentz AM; Wong RL; Kupper H; Luo MP
Arthritis Rheum; 2007 Aug; 57(6):1050-7. PubMed ID: 17665483
[TBL] [Abstract][Full Text] [Related]
8. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis.
Reilly MC; Gooch KL; Wong RL; Kupper H; van der Heijde D
Rheumatology (Oxford); 2010 Apr; 49(4):812-9. PubMed ID: 20100797
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
[TBL] [Abstract][Full Text] [Related]
10. Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis.
Navarro-Compán V; Baraliakos X; Magrey M; Östör A; Saffore CD; Mittal M; Song IH; Ganz F; Stigler J; Deodhar A
Rheumatol Ther; 2023 Jun; 10(3):679-691. PubMed ID: 36820984
[TBL] [Abstract][Full Text] [Related]
11. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.
van der Heijde D; Deodhar A; Braun J; Mack M; Hsu B; Gathany TA; Inman RD; Han C;
J Rheumatol; 2014 Jun; 41(6):1095-103. PubMed ID: 24737912
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H; Sieper J; Kivitz A; Blanco R; Cohen M; Martin R; Readie A; Richards HB; Porter B;
Arthritis Care Res (Hoboken); 2017 Jul; 69(7):1020-1029. PubMed ID: 28235249
[TBL] [Abstract][Full Text] [Related]
13. Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.
Reveille JD; Deodhar A; Ince A; Chan EKH; Peterson S; Li N; Hsia EC; Kim L; Lo KH; Xu S; Harrison DD; Han C
Value Health; 2020 Oct; 23(10):1281-1285. PubMed ID: 33032770
[TBL] [Abstract][Full Text] [Related]
14. Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis.
Maksymowych WP; Gooch KL; Wong RL; Kupper H; van der Heijde D
J Rheumatol; 2010 Feb; 37(2):385-92. PubMed ID: 19955052
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
16. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.
Reveille JD; Deodhar A; Caldron PH; Dudek A; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
J Rheumatol; 2019 Oct; 46(10):1277-1283. PubMed ID: 30824635
[TBL] [Abstract][Full Text] [Related]
18. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
Braun J; Baraliakos X; Deodhar A; Baeten D; Sieper J; Emery P; Readie A; Martin R; Mpofu S; Richards HB;
Ann Rheum Dis; 2017 Jun; 76(6):1070-1077. PubMed ID: 27965257
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
Kvien TK; Conaghan PG; Gossec L; Strand V; Østergaard M; Poddubnyy D; Williams N; Porter B; Shete A; Gilloteau I; Deodhar A
Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
[TBL] [Abstract][Full Text] [Related]
20. Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis.
Sağ S; Nas K; Sağ MS; Tekeoğlu İ; Kamanlı A
J Back Musculoskelet Rehabil; 2018; 31(3):499-505. PubMed ID: 29504521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
